Navigation Links
Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
Date:10/27/2008

Phase 3 and Open Label Extension Results Support Efficacy and Safety of Pegloticase

EAST BRUNSWICK, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that data from its pegloticase pivotal clinical studies in treatment-failure gout (TFG) patients was presented at scientific sessions during the annual meeting of the American College of Rheumatology (ACR). Four presentations focused on results from the pegloticase double blind placebo controlled Phase 3 pivotal studies. Data from the interim results of the uncontrolled open label extension (OLE) study were included as well. The data presented at the sessions extended the positive clinical results previously reported by the Company and further demonstrated the safety and efficacy of this novel biological drug in treatment for up to one year or longer. The presentations included results and analyses in three areas not previously discussed that included the effect of pegloticase on gout tophi, gout flares, and the immune response to pegloticase in patients with long-term treatment.

The results from the OLE study were consistent with findings from the Phase 3 studies, both of which met the primary endpoint relating to the normalization of plasma uric acid, for pegloticase 8 mg intravenous infusion every 2 weeks or every 4 weeks. A substantial subset of patients who completed the Phase 3 clinical trials and enrolled in the OLE continued to show improvements in the resolution of their signs and symptoms of treatment-failure gout with continuing pegloticase treatment, extending the positive clinical results seen in Phase 3. The two clinical efficacy endpoints of most interest, gout flares and gout tophi, showed an increasing proporti
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
2. Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health
3. UKs NICE Recommends Spinal Cord Stimulation for Patients with Chronic Neuropathic Pain
4. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. AdvanDxs PNA FISH(TM) Test Shown to Reduce Mortality by 42% for Patients With Hospital-Acquired Enterococcus faecium Bloodstream Infections
6. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
7. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
8. Novel Mass Spectrometry-based Assay Reveals Degradation and Low Levels of Bioactive B-type Natriuretic Peptide (BNP) in Patients with Heart Failure
9. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
10. DaVita Treats Thousands of Dialysis Patients in Wake of Hurricane Ike
11. Fujitsu PalmSecure and HT Systems PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... provider of strategic communications services to corporations and organizations preparing for ... United States and Europe , today ... to the firm,s Washington, D.C. office. ... years of service as Associate Commissioner for the Office of External ...
(Date:1/14/2014)... 2014 EquitiesIQ, a leading informational research ... Alliqua is an emerging biomedical company acquiring, developing, manufacturing, ... market. , Free report download: http://equitiesiq.com/reports/alliqua/ , ... management team and Board, which launched the company’s new ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... , AURORA, Ontario, Sept. 8 Helix BioPharma Corp. (TSX, ... announced private placement of 6,625,000 units at $2.05 per unit. ... and one common share purchase warrant, with each common share purchase warrant ... the Company at a price of $2.87 for up to three years ...
... , CAMBRIDGE, Mass., Sept. 8 ... the development of next-generation cellulosic ethanol and high-performance specialty enzymes, ... of the Company,s common stock will take effect after market ... continue to trade on the NASDAQ Global Market under the ...
... , FORT LAUDERDALE, Fla., Sept. 8 South Florida ... launched an important joint event with the state,s life sciences organization, ... Lauderdale on August 27, to hear experts from Scripps Florida, University ... and information technology. , , Presentations ...
Cached Biology Technology:Helix BioPharma Closes Private Placement 2Helix BioPharma Closes Private Placement 3Verenium Announces Reverse Stock Split to Take Effect September 9 2Verenium Announces Reverse Stock Split to Take Effect September 9 3Verenium Announces Reverse Stock Split to Take Effect September 9 4South Florida Technology Alliance and BioFlorida Joint-Event Draws Big Names and Big Crowd 2South Florida Technology Alliance and BioFlorida Joint-Event Draws Big Names and Big Crowd 3
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a ... life-threating illness in very young and elderly populations. ... enters host cells through the fusion protein RSV ... interfering peptides that prevent bundle formation limit RSV ... susceptible to degradation. In this issue of the ...
(Date:4/17/2014)... and Professor Luca Razzari of the nergie Matriaux ... grants from the John R. Evans Leaders Fund ... the acquisition of state-of-the-art biotech and nanophotonics equipment. ... from the Ministre de l,Enseignement suprieur, de la ... (MESRST). These new laboratories will help us develop ...
(Date:4/17/2014)... to produce hydrogen sulfide in order to properly multiply ... from the Center for Craniofacial Molecular Biology at the ... Songtao Shi, principal investigator on the project, said the ... the flow of calcium ions. The essential ions activate ... or the creation of new bone tissue, and keeps ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6New state-of-the-art biotech and nanotech equipment for INRS 2
... a protein critical to enabling the brain to talk to ... researchers report. The finding that an antibody to ... brain-muscle interaction helps explain why as many as 10 percent ... muscle weakness, yet their blood provides no clue of the ...
... of brain cell that tamps down stem cell activity ... progeny, Johns Hopkins researchers report. Understanding how these new ... how to behave is of special interest because changes ... as Alzheimer,s, mental illness and aging. "We,ve ...
... have in common? Based on work by scientists at the European ... same part of the brain reacts to both. In a study ... at least in mice different types of fear are ... out those fears in the same way. The findings could have ...
Cached Biology News:New cause found for muscle-weakening disease myasthenia gravis 2New cause found for muscle-weakening disease myasthenia gravis 3SIGNAL found to enhance survival of new brain cells 2What are you scared of? 2
... variety of solvent vapors that can contaminate and ... (GCF400) allows for the collection of liquid into ... cooling time minimizes waiting period., , Easy ... , -50?C Temerature for ...
... Protein Phosphatase-2A (PPase-2A) is a serine/threonine ... It is isolated as the heterodimer of ... has the ability to dephosphorylate the a-subunit ... subunit, PPase-2A has broad substrate specificity and ...
... is a high performance spectral scanning ... incubator. With the advanced SkanIt Software ... for drug discovery assay development. Varioskan ... intensity, time-resolved fluorescence and photometric assays ...
... Effectively condenses and traps a wide variety of ... oil. Easy-to-use glass condensation flask (GCF400) allows for the ... easy draining. Rapid cooling time minimizes waiting period., ... high volatile solvents , ...
Biology Products: